Nirmatrelvir-ritonavir for COVID-19
Emily G. McDonald, Todd C. Lee
Abstract
Treatment is indicated for adult (≥ 18 yr) outpatients with nonhypoxic COVID-19 who are at high risk of severe disease progression (e.g., advanced age, comorbidity, unvaccinated or immunosuppressed).[1][1],[2][2] According to available data, patients with 5% risk of hospital admission have an
Topics & Concepts
Coronavirus disease 2019 (COVID-19)RitonavirComorbidity2019-20 coronavirus outbreakMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusMEDLINEDiseaseInternal medicineEmergency medicineIntensive care medicinePediatricsFamily medicineVirologyHuman immunodeficiency virus (HIV)Viral loadInfectious disease (medical specialty)OutbreakAntiretroviral therapyBiologyBiochemistryInfectious Encephalopathies and EncephalitisCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research